

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* Cannon Kara (Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE (Street) NEW YORK, NY 10022 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/24/2022	3. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]		
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Operating Officer		5. If Amendment, Date Original Filed(Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, \$0.01 Par Value	22,614	I	401k

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (to acquire Common Stock)	02/11/2023 ⁽¹⁾	02/11/2027	Common Stock	87,500	\$ 3.36	D	
Stock Option (to acquire Common Stock)	01/11/2022 ⁽¹⁾	01/11/2026	Common Stock	55,400	\$ 2.63	D	
Stock Option (to acquire Common Stock)	02/24/2021 ⁽¹⁾	02/24/2025	Common Stock	55,400	\$ 2.2	D	
Stock Option (to acquire Common Stock)	01/03/2020 ⁽¹⁾	01/03/2024	Common Stock	52,000	\$ 2.8	D	
Stock Option (to acquire Common Stock)	07/31/2019 ⁽¹⁾	07/30/2023	Common Stock	35,000	\$ 4.42	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Cannon Kara C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022			Chief Operating Officer	

Signatures

/s/ Kara Cannon		03/28/2022
-----------------	--	------------

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The stock options have a five-year term and will vest in three equal installments, one on the first anniversary of the grant date, the second on the second anniversary of the grant date and the third on the third anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.